Dose Formulation Analysis is an essential step in regulated nonclinical studies. Robust analytical methods, rapid turnaround, and efficient communication helps deliver your GLP studies’ dose formulation analysis results on time

At KCAS, our scientific expertise allows us to develop methods that achieve your study requirements. Our experts understand complexities in dose formulation vehicles. This means we develop validated methods quickly, using the appropriate analytical tools for your studies.

KCAS delivers high-quality data on time to our customers, helping them with their drug development needs.

KCAS has significant experience in all aspects of dose formulation analysis. Methods utilizing UV/Vis or Fluorescence detectors, whichever is appropriate for your protein or small molecule. In addition, KCAS has substantial infrastructure and decades of expertise in qualitative and quantitative separations utilizing HPLC mass spectrometry detection of peptide drugs. KCAS has experience with all major formulation dosage forms including solid oral, semisolid, liquid, and medicated feeds.

Technical Capabilities

Following GLP FDA 21CFR58 OECD, KCAS develops and validates our Dose Form Testing Methods (UHPLC-UV, UHPLC-FLD, or LC-MS/MS) for precision, accuracy, linearity, range, specificity, and limit of quantitation. We follow dose formulation validation guidelines from AAPS. After method development and validation of test methods for each vehicle, we perform GLP formulation stability studies in parallel with Dose Formulation Studies. Formulation Stability Studies cover each Test Method across all Dose Form Studies. Using the lowest and highest study formulation concentrations, we assess the longest storage time across studies and all formulation storage / shipping temperatures.

Key KCAS DFA Differentiators

  • Fast method transfer, development, and GLP validation
  • Method assessments for proof of concept
  • GLP formulation stability covering all your dose form studies
  • Professional eCTD FDA-ready GLP study reports
  • Homogeneity, compatibility, and in-use stability studies
  • Single-contact project management
  • Certificate of testing preclinical analysis for test and control articles
  • State-of-the-art 70,0000 sq ft analytical laboratory
  • Method Development with limited API during the CMC stage
  • GLP analysis of dose form suspensions, solutions, capsules, or feed
  • Quantitative analysis of challenging formulations using RP-UHPLC-UV, SEC-HPLC-UV, LC-MS/MS, NanoDrop
  • Expertise with difficult formulations of proteins, peptides, biologics, and polymers